Pseudomonas aeruginosa has become an important cause of infection, especially in patients with compromised host defense mechanisms. It is the most common pathogen isolated from patients who have been hospitalized for more than one week. Signs and symptoms include pneumonia, fever, fatigue, itchy rash, bleeding ulcers and headache. Risk factors include age and weakened immune system.
Pseudomonas aeruginosa Infections - Companies Involved in Therapeutics Development are Achaogen Inc, Adenium Biotech ApS, Aeolus Pharmaceuticals Inc, AlgiPharma AS, AmpliPhi Biosciences Corp, AnGes MG Inc, Arch Biopartners, Inc., Aridis Pharmaceuticals LLC, Arno Therapeutics Inc, AstraZeneca Plc, Biolytics Pharma, Catabasis Pharmaceuticals Inc, Cellceutix Corp, CSA Biotechnologies LLC, Cyclacel Pharmaceuticals Inc, Evaxion Biotech ApS, F. Hoffmann-La Roche Ltd, FOB Synthesis Inc, GlaxoSmithKline Plc, Helix BioMedix Inc, Hsiri Therapeutics LLC, Immun System IMS AB, Insmed Inc, Lascco SA, Laurent Pharmaceuticals Inc, LegoChem Biosciences Inc, Lytix Biopharma AS, MedImmune LLC, Melinta Therapeutics Inc, Microbiotix Inc, Nosopharm SAS, Novabiotics Ltd, Omnia Molecular Ltd, Peptilogics Inc, Pfizer Inc, Pherecydes Pharma SA, Phico Therapeutics Ltd, Polyphor Ltd, Procarta Biosystems Ltd, Sanofi, Sarepta Therapeutics Inc, Sealife PHARMA GMBH, Sequoia Sciences Inc, Shionogi & Co Ltd, Soligenix Inc, Syntiron LLC, Tetraphase Pharmaceuticals Inc, Varinel Inc, Vaxdyn SL and Zambon Company SpA.
The Pseudomonas aeruginosa Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Pseudomonas aeruginosa Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 4, 3, 52, 22 and 2 respectively.
Similarly, the Universities portfolio in Preclinical, Discovery and Unknown stages comprises 11, 12 and 1 molecules, respectively.Pseudomonas aeruginosa Infections.
Pseudomonas aeruginosa Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Complete research report of 250 pages with TOC is available at www.reportsnreports.com/contact…ame=781981
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Pseudomonas aeruginosa Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Pseudomonas aeruginosa Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pseudomonas aeruginosa Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pseudomonas aeruginosa Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pseudomonas aeruginosa Infections (Infectious Disease)
Access this report at www.reportsnreports.com/purchas…ame=781981
Reasons to access
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pseudomonas aeruginosa Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pseudomonas aeruginosa Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.